Notable Stock to Watch: BioSig Technologies (NASDAQ:BSGM)

BioSig Technologies (NASDAQ:BSGM) changed 3.93% to recent value of $9.25. The stock transacted 417302 shares during most recent day however it has an average volume of 185.35K shares. It spotted trading -7.22% off 52-week high price. On the other end, the stock has been noted 164.29% away from the low price over the last 52-weeks.

 BioSig Technologies (NASDAQ:BSGM) a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace,  announced that the Company has issued their June 2019 Shareholder Letter, highlighting successful patient cases using PURE EP™ System at three different medical centers, strengthening of patent portfolio and publication strategy, inclusion on the Russell 3000® Index, and other milestones moving toward commercialization.

Recent Company Highlights:

Successfully conducted patient cases using PURE EP™ System at Indiana University School of Medicine, Texas Cardiac Arrhythmia Institute and Greenville Memorial Hospital

Announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, 2019

Announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its PURE EP™ Simulator

Received a total of $4.6 million in warrant and option exercises in Q1 and Q2 2019

Announced that the U.S. Patent Office allowed 33 patent claims covering its PURE EP(tm) System.

Announced that Jerome Zeldis, M.D., Ph.D, former Chief Medical Officer of Celgene, re-joined BioSig as an Independent Director

BioSig’s manuscript entitled, Evaluation of Real Time Catheter Tissue Contact using Unipolar Intracardiac Signal Morphology was accepted at International Engineering in Medicine and Biology Conference 2019

Participated at the Heart Rhythm Society’s 40th Annual Scientific Sessions in San Francisco, CA

Appointed Frank J. Quintero and D.A. Wallach to Advisory Board

Completed private placement for $8,620,506 in March 2019

Appointed Dr. Barry Keenan, Ph.D, MBA, PMP to head up BioSig’s advanced product development.

The highlight of first five months of 2019 was, of course, the success of our first patient cases using PURE EP™ System at three different medical institutions, stated Mr. Kenneth Londoner, Founder, Chairman and CEO of BioSig Technologies. BioSig attended the Heart Rhythm Society’s 40th Annual Scientific Sessions and received outstanding feedback and support from the medical and scientific community. We have been working diligently towards commercialization and are excited that the PURE EP™ System has delivered great results during the first phase of external evaluation. Every area of our business has been solidified in the first five months of 2019 – strong balance sheet, exceptional human talent, first class clinical partners and robust intellectual property portfolio all mean that we’ve never been stronger as a Company. We would like to thank all our loyal shareholders – we never take your support for granted and will continue to work tirelessly on your behalf. Its earnings per share (EPS) expected to touch remained -17.30% for this year

 The company has 19.45M of outstanding shares and 13.67M shares were floated in the market. According to the most recent quarter its current ratio was 11 that represents company’s ability to meet its current financial obligations. The price moved ahead of 27.78% from the mean of 20 days, 28.27% from mean of 50 days SMA and performed 69.38% from mean of 200 days price. Company’s performance for the week was 16.94%, 31.95% for month and YTD performance remained 116.63%.

Leave a Reply

Your email address will not be published. Required fields are marked *